Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRB3 | P28472 | 20/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 18/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 18/20 | 0.43 |
| ▸ | GABRP | O00591 | 15/20 | 0.43 |
| ▸ | GABRD | O14764 | 15/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 15/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 15/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 15/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 15/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 15/20 | 0.43 |
| ▸ | GABRA4 | P48169 | 15/20 | 0.43 |
| ▸ | GABRE | P78334 | 15/20 | 0.43 |
| ▸ | GABRA6 | Q16445 | 15/20 | 0.43 |
| ▸ | GABRG1 | Q8N1C3 | 15/20 | 0.43 |
| ▸ | GABRG3 | Q99928 | 15/20 | 0.43 |
| ▸ | GABRQ | Q9UN88 | 15/20 | 0.43 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2840412 | 0.95 | GABRB3 (0.42) | GABRB3GABRA2GABRB2GABRPGABRD | |
| SCHEMBL2835863 | 0.94 | GABRB3 (0.43) | GABRB3GABRA2GABRB2GABRPGABRD | |
| SCHEMBL2841648 | 0.93 | GABRB3 (0.48) | GABRB3GABRA2GABRB2GABRPGABRD | |
| SCHEMBL2835106 | 0.87 | GABRB3 (0.48) | GABRB3GABRA2GABRB2GABRPGABRD | |
| SCHEMBL2836824 | 0.85 | GABRP (0.35) | GABRB3GABRA2GABRB2GABRPGABRD | |
| SCHEMBL2837413 | 0.85 | GABRB3 (0.44) | GABRB3GABRA2GABRB2GABRPGABRD | |
| SCHEMBL2842481 | 0.85 | GABRB3 (0.41) | GABRB3GABRA2GABRB2GABRPGABRD | |
| SCHEMBL2839803 | 0.85 | GABRB3 (0.44) | GABRB3GABRA2GABRB2GABRPGABRD | |
| SCHEMBL7027650 | 0.83 | GABRB3 (0.49) | GABRB3GABRA2GABRB2GABRPGABRD | |
| SCHEMBL19043949 | 0.83 | GABRP (0.33) | GABRB3GABRA2GABRB2GABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2550962-A2 | Compositions comprising an aryl pyrazole and/or a formamidine, methods and uses thereof | Merial Limited (US) | 2013-01-30 | — | — | EP | claimed |
| EP-2364147-A2 | COMPOSITIONS COMPRISING 1-ARYLPYRAZOLE ALONE OR IN COMBINATION WITH FORMAMIDINE FOR THE TREATMENT OF PARASITIC INFECTION | Merial Limited (US) | 2011-09-14 | — | — | EP | claimed |
| WO-2010059529-A2 | COMPOSITIONS COMPRISING AN ARYL PYRAZOLE AND/OR A FORMAMIDINE, METHODS AND USES THEREOF | MERIAL LIMITED (US) | 2010-05-27 | — | — | WO | claimed |
| US-20100125097-A1 | COMPOSITIONS COMPRISING AN ARYL PYRAZOLE AND/OR A FORMAMIDINE, METHODS AND USES THEREOF | MERIAL, INC. | 2010-05-20 | — | — | US | claimed |
| EP-3096739-B1 | TOPICAL DELIVERY FORMULATION | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-2550962-B1 | Compositions comprising an aryl pyrazole and/or a formamidine, methods and uses thereof | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) | 2019-10-30 | — | — | EP | disclosed |
| US-9756852-B2 | Topical delivery formulation | MERIAL INC. (US) | 2017-09-12 | — | — | US | disclosed |
| EP-3096739-A1 | TOPICAL DELIVERY FORMULATION | Merial, Inc. (US) | 2016-11-30 | — | — | EP | disclosed |
| US-9339033-B2 | 1-aryl-5-alkyl pyrazole derivative compounds, processes of making and methods of using thereof | MERIAL, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| EP-2035390-B1 | 1-Aryl-5-alkyl pyrazole derivative compounds, processes of making and methods of using thereof | MERIAL INC (US) | 2015-12-09 | — | — | EP | disclosed |
| US-9173728-B2 | Multi-cavity container having offset indentures for dispensing fluids | MERIAL INC. (US) | 2015-11-03 | — | — | US | disclosed |
| WO-2015109312-A1 | TOPICAL DELIVERY FORMULATION | MERIAL INC. (US) | 2015-07-23 | — | — | WO | disclosed |
| EP-2550962-A2 | Compositions comprising an aryl pyrazole and/or a formamidine, methods and uses thereof | Merial Limited (US) | 2013-01-30 | — | — | EP | disclosed |
| EP-2465851-A1 | 1-Aryl-5-alkyl pyrazole derivative compounds, processes of making and methods of using thereof | Aventis Agriculture (FR) | 2012-06-20 | — | — | EP | disclosed |
| EP-2364147-A2 | COMPOSITIONS COMPRISING 1-ARYLPYRAZOLE ALONE OR IN COMBINATION WITH FORMAMIDINE FOR THE TREATMENT OF PARASITIC INFECTION | Merial Limited (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20100249194-A1 | 1-ARYL-5-ALKYL PYRAZOLE DERIVATIVE COMPOUNDS, PROCESSES OF MAKING AND METHODS OF USING THEREOF | MERIAL, INC. | 2010-09-30 | — | — | US | disclosed |
| US-7759381-B2 | 1-aryl-5-alkyl pyrazole derivative compounds, processes of making and methods of using thereof | AVENTIS AGRICULTURE (FR) | 2010-07-20 | — | — | US | disclosed |
| WO-2010059529-A2 | COMPOSITIONS COMPRISING AN ARYL PYRAZOLE AND/OR A FORMAMIDINE, METHODS AND USES THEREOF | MERIAL LIMITED (US) | 2010-05-27 | — | — | WO | disclosed |
| US-20100125097-A1 | COMPOSITIONS COMPRISING AN ARYL PYRAZOLE AND/OR A FORMAMIDINE, METHODS AND USES THEREOF | MERIAL, INC. | 2010-05-20 | — | — | US | disclosed |
| US-20080031902-A1 | 1-Aryl-5-alkyl pyrazole derivative compounds, processes of making and methods of using thereof | MERIAL, INC. | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249194-A1 | 1-ARYL-5-ALKYL PYRAZOLE DERIVATIVE COMPOUNDS, PROCESSES OF MAKING AND METHODS OF USING THEREOF | CBR3, CBR1, NR5A2 | GABRB3 1201/4885GABRA2 1488/4885GABRB2 1394/4885 |
| US-20080031902-A1 | 1-Aryl-5-alkyl pyrazole derivative compounds, processes of making and methods of using thereof | CBR3, CBR1, NR5A2 | GABRB3 1160/4885GABRA2 1437/4885GABRB2 1325/4885 |
| US-20100125097-A1 | COMPOSITIONS COMPRISING AN ARYL PYRAZOLE AND/OR A FORMAMIDINE, METHODS AND USES THEREOF | TYR, CAT, NAT1 | GABRB3 2559/4885GABRA2 2349/4885GABRB2 2986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.